Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002976 · ClinicalTrials.gov registry record · Phase 3
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,108
- Enrollment target
NCT00002976: Clinical Trial Phase 3 study, sponsored by Gynecologic Oncology Group.
NCT00002976 is a Phase 3 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 2,108 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002976, a Phase 3 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,108 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
Interventions
- DRUG conjugated estrogens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,108 participants |
| Start Date | 1997-06 |
| Phase | Phase 3 |
Why NCT00002976 stopped before completion
NCT00002976 is an interventional study that assigns participants to a tested intervention. Its 2,108 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 1 intervention - of which conjugated estrogens is the first listed.
NCT00002976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002976 about?
NCT00002976 is a clinical study titled "Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer". RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen ...
What is the current status of trial NCT00002976?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,108 participants. The study started on 1997-06.
What interventions are being tested in trial NCT00002976?
The interventions under investigation include: conjugated estrogens (DRUG).
Who is sponsoring clinical trial NCT00002976?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002976's enrollment target sits among peer trials
2,108 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia